

July 14, 2021

BSE Limited

Corporate Relationship Department
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001.

National Stock Exchange of India Limited

Listing Department
Exchange Plaza, Bandra-Kurla Complex,
Bandra (East),
Mumbai – 400 051.

Scrip code: **512529**

Symbol: **SEQUENT**

Subject: Press Release – SeQuent announced EUGMP approval for its tablets dosage form in Turkey

Dear Sir / Madam,

We enclose herewith a copy of Press Release that is being issued by the Company, in connection with the above-mentioned subject.

You are requested to take the same on record.

Thanking you.

Yours faithfully

For **Sequent Scientific Limited**

A handwritten signature in blue ink, appearing to read "Krunal Shah".

Krunal Shah

Company Secretary & Compliance Officer



Encl.: as above

SeQuent Scientific Limited

301/A, 'Dosti Pinnacle', Plot No. E7, Road No. 22, Wagle Industrial Area,
Thane(W), Mumbai - 400604, India

Tel: +9122 4111777 | CIN: L99999MH1985PLC036685

<http://www.sequent.in>

Sequent Scientific announces EUGMP approval for its tablets dosage form in Turkey

Mumbai, July 14, 2021: SeQuent Scientific Limited (SeQuent) today announced the EUGMP approval of its tablets dosage manufacturing line in Turkey. The approval was further complimented by the successful renewal of EUGMP license for 8 other manufacturing lines for various dosage forms including beta-lactam, non-beta lactam, terminal sterilization, mastitis, powder beta-lactam, aerosol, pesticide, and solids in Turkey. In addition to the EUGMP, the manufacturing lines in Turkey also hold GMP certificates from Turkish, Saudi, Ethiopian and Sudanese authorities. With these approvals, Alivira now has multiple EUGMP approved facilities globally, allowing it to better serve the needs of its customers in the regulated markets of Europe, and access to alternative manufacturing sites to ensure supply of high quality products.

With over 120 product registrations, SeQuent is the third-largest player in the Turkish ruminant market with a consolidated market share of ~10%, operating through its 100% subsidiaries of Provet and Topkim. The company has already embarked upon significant expansion in Turkey to meet the growing requirements of the local market along with leveraging the sites for European and other strategic markets.

About SeQuent Scientific Limited

SeQuent Scientific Limited (BSE-512529, NSE-SEQUENT) headquartered in Mumbai, India with a global footprint, operates in the domains of Animal Health (Alivira) and Analytical Services. SeQuent has eight manufacturing facilities based in India, Spain, Germany, Brazil and Turkey with approvals from global regulatory bodies including USFDA, EUGMP, WHO, TGA among others. Its Vizag facility is India's first and only USFDA approved facility for veterinary APIs.

For details, feel free to contact:

Tushar Mistry

Chief Financial Officer
Tel: +91 22 4111 4717
tushar.m@sequent.in

Diwakar Pingle

Christensen Investor Relations
Tel : +91 22 4215 0210
sbubna@christensenir.com

Abhishek Singhal

Investor Relations Consultants
abhishek.s@sequent.in

Registered Office

301/A, 'Dosti Pinnacle', Plot No. E7, Road No. 22, Wagle Industrial Area, Thane (W), Maharashtra, India

CIN: L99999MH1985PLC036685

BSE Code:512529 | NSE: SEQUENT

ISIN: INE807F01027 | REUTERS: EQU.BO

Website: www.sequent.in